Darbepoetin alfa

达依泊汀α

Report date: 2026/05/26 20:00:28

Base Information

Drug NameDarbepoetin alfa
Drug Alias NameDarbepoetin α阿法达贝汀（安进）Darbepoetina alfa (Amgen)达促红素α （安进）达贝泊汀α（安进） +[20] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsSolid tumoursNeurodevelopmental DisordersDiabetes Mellitus +[30] 
Global Approved IndicationsAnemiaKidney Failure, Chronic
Approved Indications in ChinaAnemia
Original Approved Country/TerritoryEU
Original Approved Date2001/06/08
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin Co LtdAmgen Europe BvKyowa Hakko Kirin Co Ltd +[6] 
Inactive CompaniesUtah State UniversityShowa University School Of MedicineOngin Company Ltd +[14] 
Active IndicationsNeurodevelopmental DisordersAnemiaKidney Failure, Chronic +[4] 
Inactive IndicationsSolid tumoursDiabetes MellitusInfant, Newborn, Diseases +[26] 

Other Information

ATC CodeB03XA02
Related LinksWikipediaDrugBankKEGG